カテゴリ： GlobalData, アメリカ, 企業調査

Intrexon Corp (XON)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Intrexon Corp (XON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013974
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：142
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Intrexon Corp (Intrexon), formerly Genomatix Corp is a provider of therapeutic solutions. The company operates through its divisions such as human therapeutics, protein production, industrial products, agricultural biotech, and animal sciences. Its human therapeutics division develops therapeutic product candidates for lysosomal storage diseases, hematological disorders, metabolic diseases, infectious diseases, and autoimmune disorders. Intrexon’s UltraVector platform produces and optimizes custom, complex gene systems; mAbLogix platform enables production of B-cell libraries for discovery of antibodies. The company offers RheoSwitch therapeutic system for inducible expression of single and multi-gene systems through an activator ligand. It has partnership with the channel of network collaborators and joint ventures to commercialize its technologies. Intrexon is headquartered in Germantown, Maryland, the US.

Intrexon Corp (XON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Intrexon Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Intrexon Corp, Medical Devices Deals, 2011 to YTD 2017 13
Intrexon Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Intrexon Corp, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Intrexon Acquires Laboratory Operations From Codexis US$1.5 Million 18
Venture Financing 19
Intrexon Raises USD29 Million in Venture Financing 19
Intrexon Raises US$75 Million In Extended Series F Financing 20
ActoGeniX Raises US$14 Million In Series B Financing 21
Intrexon Raises Additional US$25 Million In Series F Financing 23
Medistem Raises Funds Through Venture Financing 24
Intrexon Secures US$1.1 Million In Venture Financing 25
Immunologix Raises US$0.25 Million In Venture Financing 26
Intrexon Raises US$100 Million In Series E Financing 27
Intrexon Secures Additional US$11 Million In Venture Financing 28
Partnerships 29
Intrexon and Arch Pharmalabs Enter into Agreement 29
Intrexon and Johnson Matthey Enter into Agreement 30
ZIOPHARM, Intrexon Enter into Agreement with NCI 31
Intrexon Forms Joint Venture with White Rock Capital Partners 32
Intrexon Partners with Relieve Genetics 33
Intrexon Partners with Exotech Bio 34
Fibrocell Science Enters into Agreement with Intrexon 35
Intrexon Enters into Research Agreement with Janssen Pharma 36
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 37
Intrexon Enters into Partnership with Synthetic Biologics 38
Intrexon Enters into Co-Development Agreement with Oragenics 39
Intrexon Enters into R&D Agreement with National Cancer Institute 40
Stallergenes Exercises Option for Co-Development Agreement with ActoGeniX 41
Ziopharm Expands Co-Development Agreement with Intrexon 42
Fibrocell Science And Intrexon Expand Co-Development Agreement For Hypermobility-Type Ehlers-Danlos Syndrome 43
Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 45
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 46
OvaScience And Intrexon Enter Into Agreement For Infertility Treatments 47
OvaScience Forms Joint Venture With Intrexon 49
Stallergenes Enters Into Co-Development Agreement With ActoGeniX 50
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 51
Oragenics Enters Into Co-Development Agreement With Intrexon 53
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 55
Soligenix Enters Into Co-Development Agreement With Intrexon 56
Sanford-Burnham Medical Enters Into Agreement With Intrexon For Stem Cell Research 57
ActoGeniX Enters Into Research Agreement With Merck 58
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 59
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 60
Medistem Enters Into Agreement With Superview Biotechnology To Develop Antibodies For Regenerative Therapies 61
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 62
BioLife Cell Bank Enters Into Research Agreement With Intrexon 64
Medistem Enters Into Co-Development Agreement With Shanghai Jia Fu Medical Apparatus 65
Adeona Pharma Enters Into Co-Development Agreement With Intrexon 66
MediStem Enters Into Co-Development Agreement With Bakoulev Center 67
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 68
Licensing Agreements 70
Genten Therapeutics Enters into Licensing Agreement with Intrexon 70
CRS Bio Enters into Licensing Agreement with Intrexon 71
Fibrocell Science Enters into Licensing Agreement with Intrexon 72
Intrexon Enters into Licensing Agreement with Merck Serono 74
ERCell Enters into Licensing Agreement with Medistem 75
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 76
Medistem Enters Into Licensing Agreement With Cytori Therapeutics 78
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 79
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 81
Medistem Enters Into Licensing Agreement With Yale University For Type 1 Diabetes 83
Halozyme Therapeutics Enters Into Licensing Agreement With Intrexon 84
Intrexon Enters Into Licensing Agreement With Novici Biotech 86
Equity Offering 87
Intrexon to Raise USD100 Million in Private Placement of Preferred Shares 87
Oragenics Raises USD4.7 Million in Private Placement of Shares 88
Intrexon Raises USD230 Million in Public Offering of Shares 90
Intrexon Raises USD116.4 Million in Public Offering of Shares 92
Oragenics Completes Private Placement Of Shares For US$4 Million 94
Intrexon Completes IPO Of Shares For US$184 Million 95
Acquisition 96
Intrexon to Acquire GenVec 96
Intrexon Acquires 100% Stake in Okanagan Specialty Fruits 98
Intrexon Acquires ActoGeniX 99
Intrexon to Acquire Remaining 41% Stake in Exemplar Genetics 101
Intrexon Acquires 51% Stake in Exemplar Genetics 102
Intrexon Completes Acquisition Of MediStem For US$26 Million 103
Intrexon Corporation Acquires Immunologix 104
Intrexon Acquires Neugenesis 105
Intrexon Acquires Agarigen 106
Intrexon Corp – Key Competitors 107
Intrexon Corp – Key Employees 108
Intrexon Corp – Locations And Subsidiaries 109
Head Office 109
Other Locations & Subsidiaries 109
Joint Venture 110
Recent Developments 111
Strategy And Business Planning 111
Mar 10, 2017: Intrexon Creates Precigen and Accelerates Strategic Review of Structural Options Related to Health Assets 111
Jan 19, 2016: Expansion of Oxitec’s Vector Control Solution in Brazil Attacking Source of Zika Virus and Dengue Fever after Positive Program Results 112
Financial Announcements 113
Nov 09, 2017: Intrexon Announces Third Quarter 2017 Financial Results 113
Aug 09, 2017: Intrexon Announces Second Quarter and First Half 2017 Financial Results 116
May 10, 2017: Intrexon Announces First Quarter 2017 Financial Results 118
Mar 01, 2017: Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results 120
Nov 09, 2016: Intrexon Announces Third Quarter 2016 Financial Results 123
Aug 09, 2016: Intrexon Announces Second Quarter and First Half 2016 Financial Results 126
May 10, 2016: Intrexon Announces First Quarter 2016 Financial Results 129
Feb 29, 2016: Intrexon Announces Fourth Quarter and Full Year 2015 Financial Results 131
Corporate Communications 134
Jun 29, 2017: Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen 134
May 18, 2017: Intrexon Appoints Dr. Mark Carnegie-Brown as CEO of Oxitec 135
Apr 27, 2017: Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors 136
Aug 08, 2016: Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer 137
Jun 30, 2016: Intrexon Appoints Fred Hassan, Distinguished Life Sciences Executive, to Board of Directors 138
Jun 06, 2016: Intrexon Announces Retirement of Samuel Broder, M.D., Head of Health Sector 139
Product News 140
May 05, 2016: Grand Cayman will use Oxitec solution to suppress wild Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, in an effort to help eliminate these diseases 140
Other Significant Developments 141
Mar 21, 2016: Intrexon Realigns Responsibilities, Augments Team 141
Appendix 142
Methodology 142
About GlobalData 142
Contact Us 142
Disclaimer 142

List of Tables
Intrexon Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Intrexon Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Intrexon Corp, Deals By Therapy Area, 2011 to YTD 2017 11
Intrexon Corp, Medical Devices Deals, 2011 to YTD 2017 13
Intrexon Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Intrexon Acquires Laboratory Operations From Codexis US$1.5 Million 18
Intrexon Raises USD29 Million in Venture Financing 19
Intrexon Raises US$75 Million In Extended Series F Financing 20
ActoGeniX Raises US$14 Million In Series B Financing 21
Intrexon Raises Additional US$25 Million In Series F Financing 23
Medistem Raises Funds Through Venture Financing 24
Intrexon Secures US$1.1 Million In Venture Financing 25
Immunologix Raises US$0.25 Million In Venture Financing 26
Intrexon Raises US$100 Million In Series E Financing 27
Intrexon Secures Additional US$11 Million In Venture Financing 28
Intrexon and Arch Pharmalabs Enter into Agreement 29
Intrexon and Johnson Matthey Enter into Agreement 30
ZIOPHARM, Intrexon Enter into Agreement with NCI 31
Intrexon Forms Joint Venture with White Rock Capital Partners 32
Intrexon Partners with Relieve Genetics 33
Intrexon Partners with Exotech Bio 34
Fibrocell Science Enters into Agreement with Intrexon 35
Intrexon Enters into Research Agreement with Janssen Pharma 36
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 37
Intrexon Enters into Partnership with Synthetic Biologics 38
Intrexon Enters into Co-Development Agreement with Oragenics 39
Intrexon Enters into R&D Agreement with National Cancer Institute 40
Stallergenes Exercises Option for Co-Development Agreement with ActoGeniX 41
Ziopharm Expands Co-Development Agreement with Intrexon 42
Fibrocell Science And Intrexon Expand Co-Development Agreement For Hypermobility-Type Ehlers-Danlos Syndrome 43
Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 45
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 46
OvaScience And Intrexon Enter Into Agreement For Infertility Treatments 47
OvaScience Forms Joint Venture With Intrexon 49
Stallergenes Enters Into Co-Development Agreement With ActoGeniX 50
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 51
Oragenics Enters Into Co-Development Agreement With Intrexon 53
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 55
Soligenix Enters Into Co-Development Agreement With Intrexon 56
Sanford-Burnham Medical Enters Into Agreement With Intrexon For Stem Cell Research 57
ActoGeniX Enters Into Research Agreement With Merck 58
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 59
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 60
Medistem Enters Into Agreement With Superview Biotechnology To Develop Antibodies For Regenerative Therapies 61
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 62
BioLife Cell Bank Enters Into Research Agreement With Intrexon 64
Medistem Enters Into Co-Development Agreement With Shanghai Jia Fu Medical Apparatus 65
Adeona Pharma Enters Into Co-Development Agreement With Intrexon 66
MediStem Enters Into Co-Development Agreement With Bakoulev Center 67
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 68
Genten Therapeutics Enters into Licensing Agreement with Intrexon 70
CRS Bio Enters into Licensing Agreement with Intrexon 71
Fibrocell Science Enters into Licensing Agreement with Intrexon 72
Intrexon Enters into Licensing Agreement with Merck Serono 74
ERCell Enters into Licensing Agreement with Medistem 75
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 76
Medistem Enters Into Licensing Agreement With Cytori Therapeutics 78
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 79
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 81
Medistem Enters Into Licensing Agreement With Yale University For Type 1 Diabetes 83
Halozyme Therapeutics Enters Into Licensing Agreement With Intrexon 84
Intrexon Enters Into Licensing Agreement With Novici Biotech 86
Intrexon to Raise USD100 Million in Private Placement of Preferred Shares 87
Oragenics Raises USD4.7 Million in Private Placement of Shares 88
Intrexon Raises USD230 Million in Public Offering of Shares 90
Intrexon Raises USD116.4 Million in Public Offering of Shares 92
Oragenics Completes Private Placement Of Shares For US$4 Million 94
Intrexon Completes IPO Of Shares For US$184 Million 95
Intrexon to Acquire GenVec 96
Intrexon Acquires 100% Stake in Okanagan Specialty Fruits 98
Intrexon Acquires ActoGeniX 99
Intrexon to Acquire Remaining 41% Stake in Exemplar Genetics 101
Intrexon Acquires 51% Stake in Exemplar Genetics 102
Intrexon Completes Acquisition Of MediStem For US$26 Million 103
Intrexon Corporation Acquires Immunologix 104
Intrexon Acquires Neugenesis 105
Intrexon Acquires Agarigen 106
Intrexon Corp, Key Competitors 107
Intrexon Corp, Key Employees 108
Intrexon Corp, Subsidiaries 109
Intrexon Corp, Joint Venture 110

★海外企業調査レポート[Intrexon Corp (XON)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Theravance Biopharma Inc (TBPH)：企業の財務・戦略的SWOT分析
    Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • PDS Biotechnology Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary PDS Biotechnology Corp (PDS Biotechnology) is a biopharmaceutical company that develops vaccines and immunotherapies for cancer and infectious disease. The company uses versamune technology that is immunostimulatory nanoparticle vaccine platform used for the development of cancer immunothera …
  • Genesis Energy Ltd：発電所・企業SWOT分析
    Genesis Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • C&A：企業の戦略・SWOT・財務情報
    C&A - Strategy, SWOT and Corporate Finance Report Summary C&A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Ichor Medical Systems Inc-製薬・医療分野：企業M&A・提携分析
    Summary Ichor Medical Systems Inc (Ichor) is a medical equipment company that commercializes electroporation technology for the delivery of vaccines and DNA drugs. The company electroporation technology is used for the treatment and prevention of debilitating diseases. Its trigrid provides DNA drugs …
  • Ocean Power Technologies Inc (OPTT)：電力：M&Aディール及び事業提携情報
    Summary Ocean Power Technologies, Inc. (OPT) is a provider of ocean energy solutions. The company harnesses the abundant wave power to draw out renewable energy; and commercializes ocean wave power conversion technology products. The company's PB3 PowerBuoy integrates patented technologies in hydrod …
  • Karachaganak Petroleum Operating BV：企業の戦略的SWOT分析
    Karachaganak Petroleum Operating BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Genextra Spa-製薬・医療分野：企業M&A・提携分析
    Summary Genextra SpA (Genextra) is a pharmaceutical company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, mono therapy and diabetes, INT- 777 for metabolic syndrome; novel HDAC and HSP90 inhibitors for the treatment of cancer; mj …
  • Navios Maritime Acquisition Corp：企業のM&A・事業提携・投資動向
    Navios Maritime Acquisition Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Navios Maritime Acquisition Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Woolworths Limited：戦略・SWOT・企業財務分析
    Woolworths Limited - Strategy, SWOT and Corporate Finance Report Summary Woolworths Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Biolase Inc (BIOL)：企業の財務・戦略的SWOT分析
    Biolase Inc (BIOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Nanomix Inc：医療機器：M&Aディール及び事業提携情報
    Summary Nanomix Inc (Nanomix) is a medical device company that develops analytical detection devices for the point of care diagnostics. The company provides Nanomix system, which is an automated system consisting of a handheld reader and self-contained assay cartridge with a carbon nanotube biosenso …
  • MIS Implants Technologies Ltd-医療機器分野：企業M&A・提携分析
    Summary MIS Implants Technologies Ltd (MIS) is a medical device company that offers advanced products and solutions for dental implantology treatment. The company offers dental implants, tools and kits, superstructures, and solutions for oral restoration and health, among others. Its implants compri …
  • Reinhart FoodService L.L.C.：企業の戦略・SWOT・財務情報
    Reinhart FoodService L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Reinhart FoodService L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Continental Grain Co：企業の戦略的SWOT分析
    Continental Grain Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Akari Therapeutics Plc (AKTX)：企業の財務・戦略的SWOT分析
    Summary Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a …
  • Ceres Power Holdings plc (CWR)：企業の財務・戦略的SWOT分析
    Summary Ceres Power Holdings Plc (Ceres Power) is an alternative energy company that develops low cost and next generation fuel cell technologies. The company carries out developing steel cell a fuel cell technology that converts natural gas and hydrogen fuel directly into electrical power and heat …
  • Penta-Ocean Construction Co Ltd：戦略・SWOT・企業財務分析
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ALSO Holding AG：企業の戦略・SWOT・財務情報
    ALSO Holding AG - Strategy, SWOT and Corporate Finance Report Summary ALSO Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Marsulex Environmental Technologies Corp：企業の戦略的SWOT分析
    Marsulex Environmental Technologies Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆